Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Verrica Pharmaceuticals Inc. | Interim CFO | Common Stock | 54.3K | $133K | $2.46 | Nov 6, 2024 | Direct |
Aceragen, Inc. | CHIEF FINANCIAL OFFICER | Stock Options (Right to Buy) | 25.4K | Jan 20, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
VRCA | Verrica Pharmaceuticals Inc. | Nov 6, 2024 | 1 | $0 | 4 | Nov 6, 2024 | Interim CFO |
VRCA | Verrica Pharmaceuticals Inc. | Nov 5, 2024 | 0 | $0 | 3 | Nov 6, 2024 | Interim CFO |
ACGN | Aceragen, Inc. | Jan 20, 2023 | 1 | $0 | 4 | Feb 2, 2023 | CHIEF FINANCIAL OFFICER |
IDRA | IDERA PHARMACEUTICALS, INC. | Jan 6, 2023 | 2 | -$85.2K | 4 | Jan 10, 2023 | CHIEF FINANCIAL OFFICER |
IDRA | IDERA PHARMACEUTICALS, INC. | Jul 6, 2022 | 1 | $0 | 4 | Jul 7, 2022 | CHIEF FINANCIAL OFFICER |
IDRA | IDERA PHARMACEUTICALS, INC. | Apr 1, 2022 | 1 | $0 | 4 | Apr 4, 2022 | CHIEF FINANCIAL OFFICER |
IDRA | IDERA PHARMACEUTICALS, INC. | Jan 24, 2022 | 1 | $0 | 4 | Jan 26, 2022 | CHIEF FINANCIAL OFFICER |
IDRA | IDERA PHARMACEUTICALS, INC. | Dec 17, 2021 | 1 | $6.15K | 4 | Dec 21, 2021 | CHIEF FINANCIAL OFFICER |
IDRA | IDERA PHARMACEUTICALS, INC. | Jul 8, 2021 | 1 | $0 | 4 | Jul 12, 2021 | CHIEF FINANCIAL OFFICER |